医学
溃疡性结肠炎
天花板(云)
治疗效果
药品
药物开发
批判性评价
治疗方法
维多利祖马布
结肠炎
重症监护医学
内科学
药理学
病理
疾病
替代医学
物理
气象学
作者
Dahham Alsoud,Bram Verstockt,Claudio Fiocchi,Séverine Vermeire
标识
DOI:10.1016/s2468-1253(21)00065-0
摘要
Increased knowledge of the intricate pathogenesis of ulcerative colitis has triggered an advance in drug development during the past two decades, resulting in the advent of several biological agents and small-molecule therapies. Although the increase in therapeutic options is positive, remission rates of patients with ulcerative colitis given new therapeutic agents in induction trials remain at a modest 20-30%, seemingly facing a so-called therapeutic ceiling. This therapeutic ceiling requires a critical appraisal and highlights the need for alternative strategies for drug development. In this Review, we objectively itemise the boundaries of therapeutic efficacy in ulcerative colitis, provide possible explanations for the shortcomings of current strategies, and propose solutions to achieve better therapeutic outcomes in ulcerative colitis.
科研通智能强力驱动
Strongly Powered by AbleSci AI